Ilford

Researchers are evaluating the efficacy, safety, and tolerability of iptacopan in adults aged 18 to 85 years with generalized Myasthenia Gravis who are positive for AChR antibodies and are on stable standard-of-care treatment. This randomized, double-blind, placebo-controlled, multicenter Phase III study aims to compare iptacopan with placebo over six months, followed by a long-term open-label extension to further assess treatment effects and safety. Participants will be randomly assigned in equal groups to receive either oral iptacopan or a matching placebo daily for six months while continuing their standard care. After this double-blind phase, all participants are offered open-label iptacopan treatment for up to 60 months. Safety follow-up assessments occur 7 and 30 days after the last study treatment dose. During the study, participants will attend regular visits to assess changes in their Myasthenia Gravis symptoms using several scales, including the MG-ADL score, QMG, MGC, and quality of life questionnaires. Researchers will monitor adverse events and corticosteroid use throughout both the core and extension phases. The total study participation can last up to about five years, including the initial treatment, extension, and follow-up periods.

Researchers are evaluating KarXT in a Phase 3, randomized, double-blind, placebo-controlled study for adults aged 55 to 90 years with mild to severe Alzheimers Disease AD who experience moderate to severe psychosis related to AD. The study aims to assess the safety and effectiveness of KarXT compared with placebo, focusing on psychosis symptoms using the Neuropsychiatric Inventory-Clinician NPI-C Hallucinations and Delusions score. Participants will be randomly assigned to receive either KarXT capsules or placebo capsules. KarXT dosing includes various total daily doses ranging from 606 mg to 20020 mg of xanomeline and trospium chloride. The treatment period lasts up to 14 weeks, during which researchers will monitor changes in psychosis symptoms and other related measures. During the trial, participants will undergo assessments including the NPI-C for hallucinations, delusions, agitation, and aggression, as well as the Clinical Global Impressions-Severity scale. Brain imaging such as MRI or CT scans must be available or performed. Study partners with daily contact will help provide information. Safety and efficacy will be monitored throughout the treatment, with the main outcome measured at the end of treatment.

Researchers are evaluating the use of artificial intelligence and machine learning-based radiomics to distinguish between benign and malignant lung nodules in patients who have previously been treated for cancer. The study focuses on incidental lung nodules detected during routine care, aiming to improve early diagnosis of lung cancer and differentiate between metastatic recurrence and new primary lung cancer. This observational study seeks to enhance current risk models by integrating imaging and blood biomarker data. Participants under active investigation or surveillance for incidental lung nodules will be included. The study involves collecting blood samples for high-dimensional immune phenotyping and analyzing imaging data to develop biomarkers that predict cancer risk. The study also explores combining blood and imaging biomarkers to improve malignancy prediction. This research builds on previous lung screening programs and aims to reduce unnecessary imaging and invasive procedures. During the study, participants will undergo regular CT scans and blood sampling to monitor lung nodules and immune profiles over time. Researchers will assess immune phenotypes and imaging characteristics to identify markers associated with cancer development or relapse. The primary and secondary outcomes will be evaluated over a 10-year period, with long-term follow-up to track changes in risk scores after tumor treatment or regression. This approach aims to support more personalized surveillance strategies for lung nodules.

This research investigates the long-term safety and tolerability of KarXT in people with psychosis associated with Alzheimers Disease. It is a Phase 3, global, open-label extension study lasting 52 weeks that enrolls subjects who have completed previous related studies CN012-0026, CN012-0027, or CN012-0056. The study focuses on ensuring that KarXT is safe for extended use in this population. Participants receive KarXT capsules at varying doses ranging from 202 mg to 66.76.67 mg taken three times daily, with total daily doses between 606 mg and 20020 mg. This open-label extension allows subjects from the earlier studies to continue treatment and monitoring under this protocol. Throughout the 52-week study, participants will be monitored for treatment-emergent adverse events, serious adverse events, and any side effects leading to withdrawal. Assessments include regular safety evaluations from the initial dose through 14 days after the final dose, totaling up to 54 weeks. Participants will work with caregivers and study staff to complete necessary evaluations and ensure adherence to study requirements.

Researchers are evaluating treatments for community-acquired pneumonia CAP, especially in patients admitted to intensive care units ICUs. This trial also adapts to study treatments for respiratory pandemics like COVID-19. The goal is to determine which treatment strategies improve outcomes for patients with severe pneumonia, using a flexible, ongoing approach that can test multiple therapies simultaneously and update as new information becomes available. Participants receive different treatment strategies based on random assignment to study groups. Treatments include various antibiotics, steroids, antivirals, immune modulators, anticoagulation methods, and ventilation strategies. Some treatment options have been closed to recruitment, reflecting the trials adaptive nature. The trial includes several domains targeting specific infections such as influenza and COVID-19, with dosing and duration guided by clinical practice and local guidelines. During the study, participants are monitored closely with assessments including survival up to 90 days, days alive without organ support in ICU, ICU and hospital length of stay, ventilator-free days, organ failure-free days, and quality of life up to 6 months. Researchers collect detailed data on patient outcomes, organ support needs, and hospital discharge status. The study runs until February 2028, with ongoing evaluation to improve pneumonia treatment strategies in ICU settings and during respiratory pandemics.

Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, and heart failure episodes in adults with hypertension that is not well controlled and who either have established cardiovascular disease or are at high risk for it. This phase 3, randomized, double-blind study aims to gather sufficient clinical outcome events to determine the drugs impact compared to placebo. Participants will receive either 300 mg of zilebesiran or a placebo through subcutaneous injection every six months, in addition to their usual antihypertensive medications that include at least two standard drugs, one being a diuretic. The study treatments are given as add-on therapy alongside the participants existing blood pressure management. The study will continue until enough cardiovascular events have occurred to assess the primary outcome. During the study, participants will be monitored for up to approximately five years. Researchers will track the time to the first occurrence of a combined endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes will also be measured at six months. Safety and efficacy will be closely followed through regular visits and assessments. The long follow-up period allows for thorough evaluation of cardiovascular outcomes and treatment effects.